Piqray receives approval in Europe for HR+/HER2- advanced breast cancer with a PIK3CA mutation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Piqray (alpelisib) received approval from the European Commission in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.

Piqray is sponsored by Novartis.

Piqray is the first and only treatment specifically approved for people with advanced breast cancer whose tumors harbor a PIK3CA mutation, which stimulates tumor growth and is associated with poor response to therapy.

This approval follows a positive opinion granted in May by the Committee for Medicinal Products for Human Use of the European Medicines Agency based on the phase III SOLAR-1 trial showing that Piqray nearly doubled median progression-free survival compared to fulvestrant alone.

Overall response rate was more than doubled when Piqray was added to fulvestrant compared to fulvestrant alone.

Table of Contents

YOU MAY BE INTERESTED IN

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan.
Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login